skip nav
National Prevention Information Network
Search Help
Other Searches: Search Organizations | Search Materials | Search Campaign Resources | Search Funding
Share Share this page on Twitter Share this page on Facebook Share this page on LinkedIn View more options to share this page E-mail this page to a colleague Print this page

<< Back


Merck's HIV Drug Isentress Fails Once-a-Day Study

Taking the HIV drug Isentress once a day is not as effective as the standard twice-daily regimen, reported drug manufacturer Merck & Co. Based on these initial results, Merck is suspending the Phase III trial of once-daily dosing. Isentress is the only HIV drug that works by blocking integrase, an enzyme that allows HIV to insert its genetic material into human DNA. Taken twice a day, Isentress is used among both previously treated and treatment-naive HIV patients. The trial enrolled 775 patients who were taking other HIV medications in addition to Isentress. One subset received 800 milligrams of Isentress once-daily, another group received the standard 400-milligram dose twice per day. After 48 weeks, HIV was lowered to undetectable levels in 83.2 percent of patients on the once-daily regimen and 88.9 percent of patients on the twice-daily schedule.
Date of Publication
Ransdell Pierson
Article Type
General media
Article Category
Medical News

Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN. News Record #56555

<< Back

Contact Us
About Us
HIV Content Notice
Privacy Policy
Policies & Disclaimers
Site Index
Help Using the CDC NPIN Web Site

CDC NPIN Searches

Search Organizations
Search Materials
Search Funding Opportunities
Search Campaign Resources
Help Using the CDC NPIN Searches

CDC NPIN Resources
STD Awareness Microsite
AIDS Gov Logo and Link CDC Logo and Link